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Background: Erlotinib (Tarceva, OSI Pharmaceuticals, Melville,
NY) is an oral, epidermal growth factor receptor tyrosine kinase
inhibitor that has antitumor activity and good tolerability in non-
small cell lung cancer (NSCLC). In particular, higher response rates
have been reported in Asian patients than in Western patients. The
aim of this study conducted by the Korean Cancer Study Group was
to evaluate the efficacy and tolerability of erlotinib monotherapy as
a palliative treatment for advanced NSCLC patients in Korea.
Patients and Methods: Patients with histologically or cytologically
confirmed stage IIIB or IV NSCLC including recurrent or metastatic
disease, with performance status from 0 to 3, were eligible either if
they had received any anticancer treatment except epidermal growth
factor receptor inhibitors or if they were unsuitable for chemother-
apy because of poor performance status. Enrolled patients were
treated with oral erlotinib at a dose of 150 mg daily until disease
progression or development of intolerable toxicity.
Results: A total of 120 patients were enrolled between January 2005
and May 2006. Forty-four patients (36.7%) were female and 72
patients were current or former smoker. Fifty percent of patients had
received one prior palliative chemotherapy regimens and 34.2% had
two or more prior palliative regimens. The overall tumor response
rate was 24.2% (95% confidence interval [CI], 16.8–32.8%) with 4
complete responses and 25 partial responses, and the disease control
rate was 56.7%. The favorable clinical variables for tumor response
were female (P  0.001), never smokers (P  0.041), and adeno-
carcinoma (P  0.001). The most common adverse event was skin
rash (78% of which grade 3 or 4 skin rash occurred in 13.3% of the
patients). With a median follow-up of 23.6 months, the median time
to progression was 2.7 months (95% CI, 2.2–3.2), and the median
overall survival was 12.9 months (95% CI, 6.9–18.8). By multivar-
iate analysis, female and development of skin rash were significantly
associated with longer time to progression and overall survival.
Conclusion: Erlotinib monotherapy showed significant antitumor
activity and an acceptable tolerability profile as a palliative treat-
ment in advanced NSCLC patients in Korea, especially in females,
never smokers, and patients with adenocarcinoma histology.
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(J Thorac Oncol. 2009;4: 1136–1143)
Non-small cell lung cancer (NSCLC) is the leading causeof cancer-related mortality in Korea and in Western
countries. Recent advances in understanding of the molecular
mechanism of the disease have translated into the launch of
molecularly targeted therapy.
Platinum-based combination regimens as a first-line
palliative chemotherapy for advanced NSCLC offer a modest
survival advantage over best supportive care, but these agents
are commonly associated with nephrotoxicity, neurotoxicity,
and myelosuppression.1 Such toxicities may preclude the use
of these regimens in elderly patients or those with poor
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performance status (PS), although some data suggest that
elderly patients can benefit from platinum-based chemother-
apy doublets.2 On the other hand, response to first-line ther-
apy is generally short lived, and disease progression fre-
quently occurs 4 to 6 months after the treatment is
discontinued.3 Because a great majority of these patients
continue to have a good PS, they are candidates for second-
line therapy. Although docetaxel, pemetrexed, and epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitors
(TKIs) such as erlotinib are recommended as salvage chemo-
therapy for patients with good PS, the effort has been re-
quired to determine the effective and well-tolerated antitumor
agents for patients who failed to first-line platinum-based
chemotherapy.4–7
Erlotinib (Tarceva, OSI Pharmaceuticals, Melville,
NY), an oral human EGFR TKI, was approved by the U.S.
Food and Drug Administration in November 2004 and by the
European Commission in September 2005 for patients with
advanced or metastatic NSCLC who have failed at least one
prior chemotherapy regimen. The previous phase III trial
(BR.21) of erlotinib monotherapy showed survival benefit for
previously treated advanced NSCLC. Of particular interest,
exploratory analysis demonstrated favorable response and
prolonged survival in Asian patients.7 Gefitinib, which is
another EGFR TKI used for NSCLC, also showed survival
benefit in Asian patients.8–10 In support of this, a recent
analysis of 1974 patients indicated that the EGFR TKI re-
sponse was significantly dependent on ethnicity (Caucasian
10% versus East Asians 33%).11
Given the favorable treatment outcome from EGFR
TKIs in Asian NSCLC patients, the Korean Cancer Study
Group conducted a multicenter prospective study to evaluate
the efficacy and tolerability of erlotinib monotherapy as a
palliative treatment for advanced NSCLC patients in Korea.
PATIENTS AND METHODS
Eligibility Criteria
Eligibility for the present clinical trial required histo-
logically or cytologically proven stage IIIB (only the cases
with malignant pleural effusion or pleural seeding)/IV, ad-
vanced or metastatic NSCLC patients who have failed stan-
dard treatment, patients who cannot receive other cytotoxic
anticancer therapy, or patients who are not medically suitable
for systemic chemotherapy. Other inclusion criteria included
age 18 years or older with a life expectancy of 3 months or
longer; measurable disease according to the Response Eval-
uation Criteria in Solid Tumors (RECIST); Eastern Cooper-
ative Oncology Group PS 3 or lower; adequate function of the
bone marrow (absolute neutrophil count 1.5  109/liter,
platelet count 100  109/liter), kidney (serum creatinine
1.5  upper normal limit (UNL) or creatinine clearance
60 ml/min), and liver (total bilirubin 1.5  UNL, aspar-
tate transaminase and alanine aminotransferase 2  UNL
(or 5  UNL, in case of liver metastasis). Females of
childbearing potential had to have a negative pregnancy test.
Patients were excluded if they had unstable systemic disease
(active infection, uncontrolled hypertension, unstable angina,
congestive heart failure, myocardial infarction within 1 year,
and serious cardiac arrhythmia requiring medication), any
other malignancies within 5 years except for adequately
treated carcinoma in situ of the cervix, or basal or squamous
cell skin cancer. Patients with brain metastases were allowed
in the study if there was no evidence of progression in the
brain after local treatment and in the absence of corticosteroid
treatment. Patients with significant eye disorders were ex-
cluded (severe dry eye syndrome, Sjogren syndrome, severe
exposure keratinitis, and any other eye disorder likely to
increase the risk of corneal epithelial lesions). Signed in-
formed consent was required for all patients. The study was
conducted according to the latest version of the Declaration
of Helsinki, and the protocol was approved by the indepen-
dent Ethics Committee and the Review Board from each
participating institution.
Treatment and Assessments
Erlotinib 150 mg tablets were given orally daily, in the
morning with 200 ml of water, and at least 1 hour before or
2 hours after ingestion of food or medication. Treatment was
continued until disease progression, patient refusal, or intol-
erable toxicity. Dose adjustment, in 50-mg decrements, was
done if grade 3 or 4 toxicity was encountered.
Before treatment, all patients underwent a complete
medical history and physical examination, chest radiography,
chest and upper abdominal computed tomography (CT) scan,
and electrocardiogram. A brain CT or magnetic resonance
imaging scan and radionuclide bone scan were optionally
performed to document the extent of the disease. Laboratory
tests included complete blood cell counts with differential
counts of white blood cell, liver function tests, serum elec-
trolytes, serum creatinine, blood urea nitrogen, and urinalysis.
The physical examination, laboratory tests, and chest
radiography were performed every 4 weeks. Tumor measure-
ments were assessed at first 4th week after treatment and then
every 8 weeks using chest and upper abdominal CT scans.
Additional assessments with CT scans were performed at
next 4th week in cases of response to treatment to confirm
tumor response. Response assessment was according to the
Response Evaluation Criteria in Solid Tumors (RECIST).12 A
minimum duration of 4 weeks was required to document a
response and the best response was recorded for each patient.
Drug-induced toxicity was assessed every 4 weeks and was
classified in accordance with National Cancer Institute Com-
mon Toxicity Criteria, version 2.0. The worst data for each
patient across all course of treatment were used in the toxicity
analysis.
Statistical Methods
The primary end point of the study was the response
rate, and secondary objectives were disease control rate
(DCR), time to disease progression, survival, and safety.
Efficacy and safety was evaluated from the basis of intent-
to-treatment. The association between tumor responses and
each of the interest variables was measured using Pearson’s
2 or Fisher’s exact tests. Baseline factors found to be
significant by univariate analysis were included in logistic
regression multivariate models to identify baseline factors
that might independently predict response and disease con-
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trol. Statistical significance was defined as p 0.05. Survival
and time to progression (TTP) were calculated from day 1 of
treatment. Survival curves were constructed using the Kaplan-
Meier method, and survival was compared using the log-rank
test. The Cox proportional hazards model was used to estimate
the hazard ratio.
RESULTS
Patient Characteristics
Between January 2005 and May 2006, 120 patients
were enrolled from 12 medical centers in Korea. Table 1
summarizes the baseline characteristics of the patients. The
median age was 61 years (range, from 33 to 83). Forty-four
patients (36.7%) were female. Most patients had a good PS of
0 or 1, but 13 (10.8%) had PS of 2 or 3. Sixteen patients
(13.3%) had stage IIIB disease, and 104 (86.7%) had stage IV
disease at study entry. Histologically, 74 patients (61.7%) had
adenocarcinoma (including 4 bronchioloalveolar carcino-
mas), 31 (25.8%) squamous cell carcinoma, and 15 other
histologic types. Sixty patients (50.0%) had failed one prior
chemotherapy regimen, 41 (34.1%) failed to respond to at
least two prior regimens, and 19 (15.8%) were treated with
erlotinib as first-line therapy. Seventy-two (60.0%) of them
were current smokers or ever smokers.
Efficacy Response
All enrolled patients received erlotinib monotherapy,
but 109 patients were assessable for efficacy and safety. Five
patients died before first evaluation because of disease pro-
gression, another five patients were not assessable because of
patients’ refusal for further treatment, and one patient was
lost to follow-up. The objective best response rate was 24.2%
(29 of 120, 95% confidence interval [CI], 16.5–31.9) with 4
complete responses and 25 partial responses. In addition, 39
patients had stable disease, producing an overall DCR of
56.7% (95% CI, 47.7–65.7). Female, never smokers, and
patients with adenocarcinoma were significantly more re-
sponsive to erolotinib than male, smokers, and patients with
nonadenocarcinoma histology, respectively; and superior
DCR was achieved in female and never smokers (Table 2).
The type of prior chemotherapeutic regimen did not affect
response rate or DCR. The occurrence of skin rash was signif-
icantly associated with treatment response to erlotinib (p 
0.047). Of note, only 7 patients of 27 patients (25.9%) with no
skin rash achieved a response better than stable disease. In
contrast, 54.3% (25 of 46) with grade 1 skin rash, 67.7% (21
of 31) with grade 3, and 93.8% (15 of 16) with grade 4 skin
rash had response better than stable disease (p  0.001).
In multivariate analyses, female (hazard ratio [HR] 
0.25; 95% CI, 0.07–0.88; p  0.031) was independently asso-
ciated with a better response rate, whereas female (HR  0.15;
95% CI, 0.06–0.38; p  0.001) and the presence of skin rash
(HR  0.22; 95% CI, 0.08–0.63; p  0.004) were indepen-
dently associated with a better DCR. Among the responders, the
median duration of response was 11.6 months (range, 2.6–18.2),
and the median duration of disease control was 5.8 months in
patients with disease controlled (range, 1.6–18.7).
Survival
With a median follow-up duration of 23.6 months
(range, 1.2–29.0), the median TTP was 2.7 months (95% CI,
2.2–3.2) and the median overall survival (OS) was 12.9
months (95% CI, 6.9–18.8) (Figure 1). The 1-year TTP and
OS rates were 21.7% and 54.3%, respectively.
Univariate analysis showed that female, histology of
adenocarcinoma, never smoker, good performance (Eastern
Cooperative Oncology Group PS 0 to 1), and the occurrence
of skin rash were significant favorable factors for prolonged
TTP and OS (Table 4). In multivariate analysis, female and
development of skin rash were significantly associated with
longer TTP and OS (Table 4). PS 0–1 was one of the good
prognostic factors for OS but not correlated with longer
TTP. In contrast, age, stage, and the number of prior
chemotherapy regimens did not retain statistical signifi-
cance in multivariate level.
Safety
At least one drug-related adverse event was observed in
106 (86.6%) of patients, but most of them were mild (grade
1 or 2) and reversible with no grade 4 toxicity (Table 3).
Ninety-three patients (77.5%) experienced drug-related
skin rash including 16 patients (13%) of grade 3, often in
association with other skin-related symptoms, such as popu-
lar or pustular rash and pruritus. In patients with grade 3 skin
TABLE 1. Patients Characteristics
Characteristics
n  120
No. of
Patients %
Age (yr)
Median 61
Range 33–83
Sex
Male 76 63.3
Female 44 36.7
ECOG PS
0 7 5.8
1 100 83.3
2 10 8.3
3 3 2.5
Stage
IIIB 16 13.3
IV 104 86.7
Histology
Adenocarcinoma 74 61.7
Squamous cell carcinoma 31 25.8
Others 15 12.5
Prior chemotherapy
None 19 15.8
One regimen 60 50.0
Two or more regimens 41 34.2
Smoking status
Current or former smoker 72 60.0
Never smoker 48 40.0
ECOG PS, Eastern Cooperative Oncology Group performance status.
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toxicity, skin rash was improved after temporary interruption
of drug or treatment with topical antibiotics and antihista-
mines. Another commonly reported adverse event was diar-
rhea (39.2%), which could be controlled if necessary with
antidiarrheal agents such as loperamide. No clinically signif-
icant deterioration in renal or hepatic function was observed
during the trial, even in patients who entered the trial with
mild or moderate functional impairment. There were no grade
3 or 4 hematologic toxicities. There was one case of suspi-
cious drug-induced interstitial lung disease that completely
resolved upon conservative treatment.
Dose reduction to 100 mg/d of erlotinib was necessary
in 22 patients (18.3%) because of grade 3 toxicities. Two
patients required short treatment interruptions, because of
prolonged grade 3 skin reaction despite dose reduction. There
were no drug-related deaths.
DISCUSSION
Erlotinib is the first and the only EGFR TKI to show
survival benefit in patients with previously treated advanced
NSCLC in a randomized, placebo-controlled trial (BR.21),7
FIGURE 1. A, Overall survival. B,
Overall time to progression.
TABLE 2. Best Response Rate and Disease Control Rate for Erlotinib Monotherapy
Response Rate Disease Control Rate
n % P n % P
Overall rate 29/120 24.2 68/120 56.7
Age
60 18/53 34.0 0.026 33/53 62.3 0.271
60 11/67 16.4 35/67 52.2
Sex
Female 19/44 43.2 0.001 37/44 84.1 0.001
Male 10/76 13.2 31/76 40.8
ECOG PS
0–1 27/107 25.2 0.732 61/107 57.0 0.828
2–3 2/13 15.4 7/13 53.8
Stage
IIIB 5/11 31.3 0.477 10/16 62.5 0.613
IV 24/104 23.1 58/104 55.8
Histology
Adenocarcinoma 25/74 33.8 0.002 47/74 63.5 0.055
Nonadenocarcinoma 4/46 8.7 21/46 45.7
Smoking status
Never smoker 16/47 34.0 0.043 35/48 74.5 0.002
Smoker 13/73 17.8 33/72 45.2
Erlotinib treatment
1st line 6/19 31.6 0.411 13/19 68.4 0.260
2nd line 23/101 22.8 55/101 54.5
Skin rash
Yes 26/93 28.0 0.080 61/93 65.6 0.001
No 3/27 11.1 7/27 25.9
ECOG PS, Eastern Cooperative Oncology Group performance status.
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particularly in Asian patients. In salvage setting, erlotinib has
similar response rate to pemetrexed or docetaxel mono-
therapy as second-line treatment,6 but spares from premedi-
cation or inconvenience from intravenous administration. In
this study, 24.2% response rate was observed with erlotinib
monotherapy in NSCLC patients, most of who had failed to
previous chemotherapy. The response rate achieved in this
study (24.2%) is considerably higher than the response rate of
8.9% observed in the BR.21 study.
One of the plausible explanations for the high response
rate observed in the study may be the ethnic difference in
prevalence of EGFR gene mutations. We have recently con-
ducted EGFR gene mutational analyses in the same cohort of
patients and observed a superior response rate (58.3%) in the
group with EGFR gene mutations as compared with the group
without EGFR mutations (16.2%) (p  0.001).13 Consistent
with previous reports, the incidence of EGFR mutations was
higher (26.1%) in Korean patients when compared with the
Western countries (10%). Importantly, we recently showed
that patients with EGFR gene mutations or gene amplification
showed both better response rate (58.3% versus 16.2%, p 
0.001; 41.7% versus 17.3%, p  0.012) and TTP (8.6 versus
2.5 months, p 0.003; 5.8 versus 1.8 months, p 0.001) and
overall survival (not reached versus 10.8 months, p  0.023;
not reached versus 10.1 months, p  0.033).13 However,
multivariate analysis revealed that EGFR gene mutation was
an independent factor associated with prolonged TTP, but not
OS, suggesting other clinical parameters such as female,
adenocarcinoma histology, or never smokers may be in-
volved in prolongation of OS.
Despite similar progression-free survival (PFS) with
BR.21 trial (2.6 months of current data versus 2.2 months of
BR.21), the current trial demonstrated longer overall survival
(12.9 months versus 6.7 months, respectively).7 The study
population of current study might have had more indolent
disease than previous studies, which includes the ethnic
differences. Many clinical trials suggested the Asian ethnicity
as good prognostic factor of survival as well as the clinico-
pathologic characteristics such as histology, PS, EGFR mu-
tations, and smoking history.7,8,14 The subgroup analysis of
BR.21 suggested Asian ethnicity as good prognostic factors
of erlotinib therapy.7 Furthermore, better survival outcomes
of Asians with EGFR TKIs also demonstrated in gefitinib
trials.8,14 However, it is unclear that Asian origins has benefits
from EGFR TKIs but not cytotoxic chemotherapy or benefits
from both modalities. Although recent two randomized trials
of gefitinib versus docetaxel could not demonstrate superior
survivals of gefitinib compared with docetaxel,15,16 the Japa-
nese trial reported longer overall survival than INTEREST
trial, which included about 20% of Asian patients (11.5–14.0
months and 7.6–8.0 months, respectively). A small phase II
trial of erlotinib monotherapy for Japanese patients as salvage
treatment also demonstrated 14.7 months of median OS.17
Although the molecular biomarkers and study designs have to
be considered, the ethnic diversity as a prognostic factor
remains to be solved.
Recently, Lilenbaum et al.18 reported the result of
randomized phase II trial of erlotinib or paclitaxel/carboplatin
chemotherapy in patients with PS 2. As the first-line treat-
ment for advanced NSCLC patients with PS 2, erlotinib
demonstrated inferior survival outcome than standard chemo-
therapy of paclitaxel and carboplatin (median OS 6.5 months
versus 9.7 months, respectively, p  0.018). PS 2 as poor
prognostic factor was also suggested in BR.21.7 As compared
with BR.21, current trial included only 10% of patients with
PS 2 or 3, whereas BR.21 did over 30%. In addition, the
subgroup of PS 2 or 3 in current study achieved only 4.7
months of median OS. Therefore, the good survival outcomes
of current study have to be considered with the majority of
good PS patients.
Erlotinib was generally well tolerated with the most
common grade 3 toxicities being skin rash and diarrhea.
The correlation between clinical efficacy of EGFR TKI ther-
apy and the occurrence of skin rash have been reported in
other TKI trials.19–22 Although skin rash may be a potentially
predictive factor for clinical efficacy and may be used as a
surrogate marker, its predictive capacity needs to be further
validated. Patients who developed skin rash were likely to
respond to erlotinib with statistical significance (p  0.047).
Particularly, more than 90% of the patients (15 of 16) with
grade 3 skin rash achieved stable disease or better to erlotinib
treatment. Its statistical significance was retained at the mul-
tivariate level (HR  0.22; 95% CI, 0.08–0.63; p  0.004)
along with female (HR  0.25; 95% CI, 0.07–0.88; p 
0.031) to predict favorable response. In patients with grade 3
skin toxicity, skin rash was improved after temporary drug
interruption. Another commonly encountered adverse event
was diarrhea, which was easily controllable with loperamide.
The adverse events of current data were overly similar
with previous results of BR.21 with differences in details.7
TABLE 3. Nonhematological Treatment-Related Adverse
Effects
Toxicity Grade
No. of Patients
(%), Total1 2 3
Skin rash 46 (38.3) 31 (25.8) 16 (13.3) 93 (77.5)
Dry skin 37 (30.8) 12 (10.0) — 49 (40.8)
Diarrhea 33 (27.5) 9 (7.5) 5 (4.2) 47 (39.2)
Myalgia 22 (18.3) 14 (11.7) 3 (2.5) 39 (32.5)
Anorexia 25 (20.8) 10 (8.3) 1 (0.8) 36 (30.0)
Emesis 23 (19.2) 7 (5.8) — 30 (25.0)
Fatigue 14 (11.7) 8 (6.7) 4 (3.3) 26 (21.7)
Mucositis 15 (12.5) 8 (6.7) — 23 (19.2)
Paronychia 11 (9.2) 5 (4.2) — 16 (13.3)
Neuropathy 13 (10.8) 2 (1.7) — 15 (12.5)
Dyspepsia 7 (5.8) 4 (3.3) — 11 (9.1)
Alopecia 9 (7.5) 1 (0.8) — 10 (7.5)
Edema 5 (4.2) 1 (0.8) 1 (0.8) 7 (5.8)
Coneal injury 4 (3.3) — 1 (0.8) 5 (4.1)
Insomnia 2 (1.7) 2 (1.7) — 4 (3.3)
Pneumonia — — 2 (1.7) 2 (1.7)
ILD — 1 (0.8) — 1 (0.8)
There was no grade 4 toxicity.
ILD, Interstitial lung disease.
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The skin rash grade 3 was 13.3% of this study and 9% of
BR.21, whereas the grade 3 anorexia was 0.8% and 6%,
respectively. Fatigue grade 3 also reported less in current
study than BR.21 (6.7% and 19%). Recent report of erlotinib
monotherapy in Japanese patients demonstrated that all study
population suffered from any adverse events. However, the
adverse events grade 3 seemed to be lower than current
study and BR.21 in terms of 3% of skin rash, 5% of diarrhea,
and 0% of fatigue.7,17 In current study, dose reduction needed
in 18.3% of patients and dose interruptions occurred in 2% of
patients, which were similar dose reduction rate and lower
treatment interruption rate of BR.21 (19% and 27%, respec-
tively).7 Although a phase II study of erlotinib in Japanese
population seemed to show lower rates of serious adverse
events, they needed more dose modifications including 23%
of dose reduction, 48.4% of dose interruptions, and 18% of
discontinuation.17 In comparison with gefitinib, which is
another EGFR TKI, previous reports of two phase II trials of
gefitinib in Korean patients demonstrated less than 3% of
grade 3 skin rashes, anorexia, and diarrhea.23,24 These
findings of Korean population showed consistency with pre-
vious gefitinib trials such as IDEAL-1, IDEAL-2, and
ISEL.8,9,14 However, there was no randomized controlled trial
of gefitinib and erlotinib. In addition, the heterogeneity of
EGFR mutation status of each trial should also be considered.
Therefore, it is inconclusive whether gefitinib has more
tolerable toxicity profiles than erlotinib.
Three agents are currently approved by the U.S. Food
and Drug Administration in the second-line setting: do-
cetaxel, pemetrexed, and erlotinib. Phase III trial comparing
standard dose docetaxel every 3 weeks with pemetrexed (500
mg/m2 every 3 weeks) demonstrated that the two regimens
were similar in clinical efficacy with lower rate of hemato-
logic toxicities in pemetrexed alone arm.6 Although the
clinical superiority of erlotinib over docetaxel or pemetrexed
has not been proven in phase III trials, erlotinib may be
preferred by patient because of no premedication, no alope-
cia, less physician’s office visits, and convenience of oral
administration. Given a high response rate in Asian patients,
a randomized clinical trial should be conducted to compare
pemetrexed or docetaxel to erlotinib as second-line treatment
even though two recent trials of docetaxel and gefitinib failed
to show survival differences.15,16 Indeed gefitinib was asso-
ciated with lower rates of treatment related adverse events
including serious adverse events, treatment discontinuation
than docetaxel, whereas noninferiority of gefitinib was veri-
fied for overall survival (HR  1.020; 95% CI, 0.905–1.150)
in INTEREST trial.15 Furthermore, the clinical benefit of
erlotinib in terms of PFS was recently reported in first-line
setting in a phase III randomized study comparing erlotinib to
TABLE 4. Prognostic Factors for Survival
TTP OS
Univariate Multivariate Univariate Multivariate
Median (mo) P HR (95% CI) P Median (mo) P HR (95% CI) P
Age
60 2.6 0.656 0.816 0.335 18.3 0.293 1.07 0.809
60 2.7 (0.54–1.23) 11.7 (0.63–1.82)
Sex
Female 8.6 0.001 0.33 0.001 NR 0.001 0.18 0.001
Male 1.8 (0.21–0.51) 5.3 (0.09–0.36)
ECOG PS
0–1 2.6 0.352 0.52 0.052 15.0 0.005 0.21 0.001
2–3 2.7 (0.27–1.01) 4.7 (0.11–0.43)
Stage
IIIB 3.8 0.301 0.58 0.072 11.7 0.604 1.32 0.489
IV 2.5 (0.32–1.05) 13.7 (0.60–2.93)
Histology
Adenocarcinoma 3.9 0.001 0.72 0.177 NR 0.001 0.76 0.329
Others 2.0 (0.45–1.16) 7.2 (0.43–1.33)
Smoking
No 5.6 0.002 0.64 0.218 NR 0.001 0.91 0.833
Yes 1.9 (0.32–1.30) 5.3 (0.36–2.30)
Erlotinib treatment
1st line 4.0 0.352 0.68 0.209 19.2 0.465 0.56 0.149
2nd line 2.5 (0.37–1.24) 12.0 (0.25–1.23)
Skin rash
Yes 2.7 0.003 0.54 0.019 19.2 0.001 0.35 0.001
No 1.7 (0.32–0.90) 4.3 (0.20–0.63)
TTP, time to progression; OS, overall survival; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; CI, confidence interval; NR, not reached.
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standard chemotherapy (paclitaxel and carboplatin) in never
smokers and Asian population (IPASS trial).25 Although final
results are pending with further survival update, PFS that was
primary end points of IPASS trial was superior in erlotinib
group, especially positive EGFR mutation status (HR 
0.741 of all patients, p  0.0001 and 0.48 of patients with
EGFR mutations, p  0.0001). This study probably provides
support for the role EGFR TKI as the first-line treatment in
subpopulation of NSCLC patients in selected patients such as
never smoker or positive EGFR mutation status.
Although gefitinib was not recommended as second-
line treatment, the questions about the efficacy of gefitinib for
selected patients such as female, adenocarcinoma, EGFR
mutation, and Asian population still remain with debate. Even
though gefitinib failed to confirm survival benefit compare
with placebo in a large phase III trial (5.6 months for gefitinib
and 5.1 months for placebo, p  0.087), East Asian patients
achieved longer survivals than other ethnical populations in
subgroup analysis (HR  0.66; p  0.010).14 The survival
benefits of East Asian patients from gefitinib also observed in
subset analysis of IDEAL-1.8,26 The original results of IDE-
AL-1 demonstrated about 8 months of median OS, which was
similar to 6–7months of IDEAL-2, whereas Japanese subset
(n  102) achieved 12.0 months of median OS with higher
response rates (27.5% versus 10.4%, respectively, p 
0.0023).8,9,26 Even though a Japanese phase III study of
gefitinib and docetaxel as second-line treatments (V-15-32
trial) showed no difference of overall survival between two
groups, recent presentation of Korean trial (ISTATA trial)
suggested the benefit of PFS for gefitinib group than do-
cetaxel group.16,27 Therefore, gefitinib as second-line treat-
ments for East Asian origin compared with single-agent
chemotherapy warrants to further investigation.
In conclusion, this study indicates that erlotinib mono-
therapy is an effective and well-tolerated regimen for Korean
patients with advanced NSCLC in salvage setting. Tumor
responses and survival outcomes for erlotinib were compa-
rable or superior to the reported results from previously tried
first- or second-line chemotherapy regimens. Therefore, er-
lotinib monotherapy was verified as the one of salvage
treatments for patients with advanced NSCLC in Korea or
Asia. This study provides the supplementary evidence for
randomized trial compared erlotinib with systemic chemo-
therapy.
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